Mutations of the BRAF gene in human cancer

Helen Davies, Graham R. Bignell, Charles Cox, +49

Nature

Somatic VariantBraf GeneGeneticsCancer GenomicsCancer Genetics +3

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, +8

New England Journal of Medicine

Patterns of somatic mutation in human cancer genomes

Christopher Greenman, Philip Stephens, Raffaella Smith, +60

Nature

Somatic MutationSomatic VariantGeneticsMedicineEpigenetics

BRAFE600-associated senescence-like cell cycle arrest of human naevi

Chrysiis Michaloglou, Liesbeth C.W. Vredeveld, Marı́a S. Soengas, +7

Nature

AgingCell DivisionMedicineCellular SenescenceHuman Naevi +1

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, +2

Nature

Signal TransductionSignaling PathwayCell RegulationMedicineReceptor Tyrosine Kinase +8

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Georgia Hatzivassiliou, Kyung Song, Ivana Yen, +18

Nature

Signaling PathwayReceptor Tyrosine KinaseMapk PathwaySystems BiologyMedicine +6

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Sonja J. Heidorn, Carla Milagre, Steven R. Whittaker, +8

Cell

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

James Tsai, John Tayu Lee, Weiru Wang, +35

Proceedings of the National Academy of Sciences

BRAF mutation predicts sensitivity to MEK inhibition

David B. Solit, Levi A. Garraway, Christine A. Pratilas, +11

Nature

Signal TransductionBraf MutationGenetic DisorderMedicineGenetics +4

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, +11

Journal of Clinical Oncology